MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' in Peripheral Neuropathic Pain

NCT03221907 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 352

Last updated 2019-03-19

No results posted yet for this study

Summary

A multi-center, randomized, double-blind, parallel, active-controlled phase III clinical trial to evaluate the efficacy and safety of 'GLA5PR GLARS-NF1 Tab.' and 'Pregabalin' in peripheral neuropathic pain

Conditions

  • Pain of Mononeuropathy

Interventions

DRUG

GLA5PR GLARS-NF1

Pregabalin tablet

DRUG

GLA5PR GLARS-NF1 placebo

tablet manufactured to mimic GLA5PR GLARS-NF1

DRUG

Pregabalin

Pregabalin capsule

DRUG

Pregabalin placebo

tablet manufactured to mimic pregabalin capsule

Sponsors & Collaborators

  • Daewon Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-11
Primary Completion
2019-01-08
Completion
2019-01-08

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03221907 on ClinicalTrials.gov